Merck: CHMP Adopts Positive Opinion For KEYTRUDA As Monotherapy For Adjuvant Treatment Of RCC
17/12 13:11
(RTTNews) - Merck (MRK) announced the CHMP of the European Medicines Agency has adopted a positive opinion recommending approval of KEYTRUDA, the company's anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurr...